Biotech / Finance

New cholesterol-fighting drug slashes heart attack risk, but at a steep price; Amgen shares drop

From Health Care
March 17, 2017 - 11:43am
Traders are worried that Repatha isn't effective enough to justify the drug's hefty price tag of over $14,500 per year.


Continue reading this article »